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ABSTRACT 
Investigation of the Oxidation/Reduction of PRMT1,  
Substrate Interaction with PRMT1, and the  
Role of Arginine Methylation in RNA Surveillance 
 
by 
 
Damon V. Nitzel, Master of Science 
Utah State University, 2013 
 
Major Professor: Dr. Joan M. Hevel 
Department: Chemistry and Biochemistry 
 
 
 Protein arginine methylation is an abundant post-translational modification 
catalyzed by protein arginine methyltransferases (PRMTs). Arginine methylation plays 
important roles in a variety of cellular pathways and human diseases. PRMT1, the 
predominant PRMT, catalyzes approximately 85% of all protein arginine methylation in 
vivo. While many details of how PRMT1 functions have been uncovered through the 
past two decades, there are many details which remain unclear, including how arginine 
methylation is regulated, how PRMT1 binds substrates, and what role PRMTs play in 
RNA surveillance. Our recent data presented in this thesis showed that reduction of the 
PRMT1 enzyme, following recombinant expression and purification, changes both 
enzymatic activity and oligomeric state. A cysteine residue(s) was found to be 
responsible for the observed redox chemistry in PRMT1 and at least one parameter in 
the kinetic mechanism, S-adenosylmethionine (AdoMet) binding, was faster with a 
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reduced enzyme. This work suggests exciting potential for the regulation of PRMTs in 
vivo by oxidative stress. 
 In addition to studying the effects of reduction/oxidation on PRMT1, a foundation 
for future experiments was laid. These experiments investigate substrate recognition by 
PRMTs and what the role arginine methylation may play in RNA processing and 
surveillance. To better understand how PRMTs selectively bind a wide variety of 
substrates, I have designed and preliminarily characterized several Hmt1 (the S. 
cerevisiae homologue of PRMT1) variants. These variants will be used for crystallization 
trials of a homogeneous complex, containing Hmt1, AdoMet, and a peptide substrate, 
capable of revealing specific chemical interactions between Hmt1 and the peptide 
substrate. To further our understanding of Hmt1’s role in RNA processing and 
surveillance, particularly in RNA degradation pathways, I extracted yeast RNA from both 
wild type and Hmt1-null cells. The RNA was probed using a S. cerevisiae whole-genome 
microarray. This analysis revealed that Hmt1 exhibits statistically significant effects in 
several broad areas including molecular function, biological processes, cellular 
components, and some KEGG pathways. The presented studies have revealed the 
exciting potential for an in vivo regulatory mechanism of PRMT1 and each study is 
primed for further investigation both in vivo and in vitro. 
(84 pages) 
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PUBLIC ABSTRACT 
Investigation of the Oxidation/Reduction of PRMT1, Substrate Interaction with PRMT1, 
and the Role of Arginine Methylation in RNA Surveillance 
 
 Enzymes are the machines of our cells. Just like machines, it takes a lot of 
energy to create them, and they then serve only the function they were created for. If we 
want to change the function of a machine, we need to modify it. Similarly, enzymes can 
be modified after their creation to give them additional function. These modifications can 
do a variety of things including activating (on) or inactivating (off) an enzyme, changing 
the enzyme’s location in the cell, and targeting the enzyme for destruction. This thesis 
focuses on a single class of enzymes, protein arginine methyltransferases (PRMTs), 
which are capable making small modifications to other proteins. This modification is 
called methylation because the enzyme transfers one or two methyl groups to specific a 
specific location(s) on the target protein (substrate).  
 This small but significant change is involved in cellular processes such as 
transcriptional regulation, DNA repair, subcellular localization, and signal transduction. 
Due to PRMTs broad involvement in the cell, it is unsurprising that protein methylation is 
involved in several types of cancer, cardiovascular disease, and many others. Detailed 
study of PRMTs to understand methyl group transfer, substrate targeting, and how they 
are controlled by the cell is essential for the development of therapeutic drugs capable of 
treating diseases associated with protein arginine methylation. This thesis presents 
studies which continue to provide insight into the function of PRMTs by addressing the 
effects of oxidative stress on PRMT1, how PRMTs interact with their substrates at the 
atomic level, and how PRMTs are involved in the processing of RNAs. 
Damon V. Nitzel 
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CHAPTER 1 
INTRODUCTION 
INTRODUCTORY BACKGROUND 
 Communication is vital for individual entities to function together to achieve 
objectives that cannot be achieved alone. Cells in our bodies use inter/intracellular 
communication, thereby working in harmony to support life. One method cells use to 
communicate is through varied protein function. Protein function can be regulated during 
creation through transcriptional regulation, genomic recombination, alternative splicing, 
and altered transcriptional termination. Existing protein function can be further expanded 
through the use of post-translational modifications (PTMs). Chemical modifications on 
proteins can lead to changes in localization, molecular interactions, proteolytic cleavage, 
total degradation, enzymatic activity, and protein stability. The primary objective of this 
document is to expand our understanding of how protein arginine methylation (one type 
of PTM) is regulated.  
 
PTMs and Cellular Signaling 
 Many PTMs are used to transmit signals both inside and outside of the cells 
including phosphorylation, methylation, acetylation, glycosylation, ubiquitination, 
nitrosylation, and lipidation to name a few. A common example of this is observed by the 
body’s response to increased glucose levels in the blood. As insulin levels increase in 
the blood and bind to the insulin receptors, the receptor undergoes a conformational 
change that induces autophosphorylation, thereby activating the subunit’s kinase 
activity1. The activated receptor kinase phosphorylates a newly bound protein, insulin 
receptor substrate (IRS-1), a modification which is then recognized by the Src-homology 
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2 domain (SH2) of the p85 subunit of Phosphatidylinositol-3-Kinase (PI-3K). This 
induced protein-protein (IRS-1 to PI-3K) interaction activates a cascade of new 
interactions and alters the activity of many enzymes which stimulates cellular responses 
to insulin such as gene expression, glycogen synthesis, and protein synthesis. Just as 
phosphorylation is a PTM used to signal cellular responses to increased insulin levels, 
many different biological signaling pathways, to be discussed later, use the post-
translational modification methylation in signal transduction.  
 
The Methyl Group Donor S-adenosyl-L-methionine 
 In order to better understand the significance of protein methylation, it is 
important to first gain a basic understanding of how biological methylation is performed. 
Biological methyltransferases (MTases), the class of enzymes which catalyze methyl 
transfer, predominantly use S-adenosyl-L-methionine (AdoMet or SAM, Figure 1-1) as a 
methyl donor. AdoMet is second only to adenosine triphosphate (ATP) in use as an 
enzyme substrate and is used in metabolic pathways including transmethylation, 
transsulfuration, and aminopropylation2. AdoMet’s favorable energetics (a low ΔG = -17 
kcal/mol) from the charged methylsulfonium center are what make it preferable over 
other methyl donors such as N5-methyltetrahydrofolate3. The AdoMet methyl group (-
CH3) is transferred by the methyltransferases and a methylated product and S-
adenosyl-L-homocysteine (AdoHcy or SAH, Figure 1-1) is generated. Methyltransferase 
substrates are vast and include macro molecules such as Proteins, DNA, RNA4,5, and 
small molecules such as arsenite6,7 and sterols8,9. Methyltransferases are generally 
thought to use an SN2-like mechanism (Figure 1-1), transferring the methyl group onto 
the target substrate via an inversion of symmetry10,11. 
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Protein Methylation 
 One form of biological methylation, protein methylation, is involved in diverse 
cellular processes such as transcriptional regulation12, DNA repair13, subcellular 
localization of proteins14, signal transduction and nuclear transport15. Protein 
methyltransferases (PMTs) predominantly methylate nitrogen (N-methylation) and 
oxygen (O-methylation) atoms of amino acid side chains. Methylation also occurs on 
carbon (C-methylation) and sulfur (S-methylation) atoms. The most prevalent type of 
methyl transfer occurs on nitrogen atoms on the side chains of lysine, arginine, histidine, 
glutamine, and asparagine16. Lysine methylation can occur as mono-, di-, or tri-
methylation on the ε-amino group of its side chain. Arginine methylation occurs as either 
mono- (MMA), asymmetrical di-methylation (ADMA), or symmetrical di-methylation 
(SDMA)17,18. The Protein Arginine Methyltransferase (PRMT) family in mammals consists 
of nine enzymes which can be classified by type of methylation as follows: type I PRMTs 
(PRMT1, 2, 3, 4, 6 and 8)catalyze the formation of MMA and ADMA, type II PRMTs 
Figure 1-1: Diagram of protein arginine methylation by PRMT1. 
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(PRMT5, 9) form MMA and SDMA, and type III PRMTs (PRMT7) are limited to formation 
of MMA19–21. The majority of work presented in this document is performed with PRMT1 
(or its S. cerevisiae homologue, heterogeneous nuclear ribonucleoprotein 
methyltransferase [Hmt1]), the predominant PRMT responsible for biological arginine 
methylation. 
 
SIGNIFICANCE 
Biological Significance 
 The arginine methylation field has rapidly expanded as awareness of the 
modification’s involvement in a vast array of cellular processes and its significance in 
organism viability has increased. The majority of protein methylation is involved in 
cellular processes such as transcriptional regulation, pre-mRNA splicing and mRNA 
transport, DNA damage repair, and signal transduction.  
 Arginine methylation is essential for developing life— PRMT1 was shown to be 
an essential protein in a study where PRMT1 null mice died in early embryonic 
development22,23. PRMT2, -3 and -4 knockouts were embyronically viable but caused the 
following varied effects respectively; abnormal fibroblast activity and increased 
resistance to apoptosis24, smaller body mass25, and smaller body mass followed by 
death shortly after birth26. These studies emphasize the importance of understanding 
how methylation is catalyzed, used as a signal, and regulated. 
 Transcriptional regulation— Protein methylation on transcriptional factors, such 
as NF-κB27, PPARxγ28, RUNX129, p5330, p30031, YY132 and histone proteins, mainly H3 
and H4, is responsible for both upregulation and repression of gene transcription. 
Generally, PRMT1 and PRMT4 are reported as transcriptional coactivators19. PRMT 1 
methylation of the transcription factor RUNX1 promotes dissociation of the transcription 
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repressor SIN3A, resulting in RUNX1 transcriptional activity29. Increased lysine 
acetylation caused by asymmetric dimethylation H4R3 by PRMT1 leads to transcriptional 
activation33–35. Alternatively, H4R3 can be symmetrically dimethylated by PRMT5 which 
recruits DNA methyltransferase DNMT3A resulting in transcriptional silencing36. These 
results and many others show the important role(s) of protein methylation in controlling 
gene expression and in response to cellular and environmental stimuli. 
 DNA damage repair— Maintaining correct DNA sequences and repairing 
damaged DNA is of high priority in cells. DNA damaged by double strand breaks (DSBs) 
is addressed by the MRN complex (MRE11/Rad50/NBS1). Meiotic recombination 11 
(MRE11) is methylated both in vitro and in vivo by PRMT137. The methylation of 
MRE11’s GAR motif is required for exonuclease activity and intra-S phase DNA damage 
response via interaction with nuclear structures38. The tumor suppressor protein p53 is 
another important player in DNA repair, binding damaged DNA and activating genes 
which promote cell cycle arrest39. PRMT5 has been shown to regulate p53’s target gene 
specificity and PRMT5 depletion results in p53 dependent apoptosis30. Interestingly, 
PRMT6 is directly involved in regulating p53 gene expression levels. PRMT6 is recruited 
to the Trip53 promoter region where it asymmetrically dimethylates H3R2 which acts as a 
signal for H3K4 trimethylation, which in turn signals gene repression
40. 
 Signal transduction— Reversible PTMs are the most prominent modifications 
used in cellular signaling; however many examples of what is thought to be irreversible 
protein arginine methylation show it as a significant signaling contributor. PRMT6 
regulates p53 gene expression levels40, described above, as well as regulating cell cycle 
progression by repressing cyclin-dependent kinase (CDK) inhibitors41. PRMT1 
interaction with the interferon α/β (IFN α/β) receptor was shown in 198442. Subsequently, 
IFN α/β-induced transcription was shown to require arginine methylation of STAT-1. 
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STAT-1 arginine methylation is required because in an un-methylated state, STAT-1 
exhibits impaired DNA binding due to the association of PIAS1, a STAT inhibitor, and 
with phosphorylated STAT-1 dimers43. In yeast cells, Hmt1 promotes the 
nucleocytoplasmic transport of mRNA-binding proteins Yra1 and Hrp1 through 
methylation44. In addition, loss of Hmt1 methylation affects the kinetics of HSP104 
mRNA production, observed in vivo by comparing wild type and Hmt1-/- strains under 
heat stress while monitoring a fluorescent signal generated by pooling mRNA in the 
nucleus44. Hmt1’s influence in heat shock protein mRNA production indicates that Hmt1 
methylation plays an important signaling role in the cellular response to heat shock. 
 Hmt1’s role in RNA surveillance and processing is becoming increasingly 
apparent. Hmt1 methylates the RNA-binding protein Npl3 during the metabolism of 
nuclear pre-mRNA45. Hmt1 methylation is inhibited by Air1/2, a component of the 
TRAMP complex, which interacts with a wide range of substrates including tRNAs, 
snoRNAs, snRNAs, ncRNAs, rRNAs, some mRNAs, and cryptic unstable transcripts46. 
The association of Air1 or Air2 with Hmt1 introduces the concept of a role of arginine 
methylation in RNA processing on non-coding RNAs (ncRNA). To further understand 
Hmt1’s role in global RNA surveillance and processing, as discussed in Chapter 4, a 
microarray experiment was performed as an exploratory technique to monitor global 
RNA levels. This experiment was based off two previous studies, one which compared 
the mRNA levels in wild type (Hmt1) and Hmt1-null (Hmt1-/-) S. cerevisiae (yeast) 
cells44, and another which analyzed levels of RNA present after RNA was allowed to 
degrade for 45 minutes in wild type and Lrp1-null (an unrelated protein) yeast cells47. In 
preparation for the microarray analysis, these two techniques were combined to prepare 
RNA that would allow comparison of total RNA level differences (not just mRNAs) in wild 
type (Hmt1) and Hmt1-null (Hmt1-/-) cells, specifically differences relating to the 
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degradation of RNAs. Genes indentified in this comparison can then be further 
investigated for interactions with Hmt1 and how they are processed because of these 
interactions. 
 
PRMT1 and Human Disease 
 Many disease states are associated with protein arginine methylation, which is 
unsurprising given arginine methylation’s involvement in so many cellular processes, a 
few of which have been discussed. The importance of proper regulation is evident in 
studies linking PRMT’s to cancer, cardiovascular disease, viral pathogenesis, spinal 
muscular atrophy, and multiple sclerosis. To impart a sense of medical relevance to my 
studies on PRMT1, I will briefly discuss the role arginine methylation is cancer and 
cardiovascular disease. 
 Arginine methylation and cancer—As previously mentioned PRMT1 and PRMT4 
(CARM1) act as general transcriptional coactivators and disregulation is likely to affect 
levels of a variety of transcriptional pathways. Increased PRMT1 mRNA levels in breast 
cancer cell lines were reported in 200748. Additionally, studies in mouse primary 
hematopoietic cells showed a chain of protein interactions controlling self renewal 
properties partly due to implicated methylation of Sam68, a well characterized PRMT1 
substrate49. Increased expression of PRMT4 is observed in castration-resistant prostate 
cancer and in aggressive breast tumor cells that also express high levels of the 
oncogenic coactivator AIB1, and AIB1’s activity and stability is regulated through 
methylation by PRMT450,51. PRMT4 presence is required for estrogen-induced 
proliferation of the MCF-7 breast cancer cell line, likely through association with AIB1 
which is required for recruitment of PRMT4 to ERα-regulated promoter regions52. In 
prostate cancer cells, PRMT4 knockdown by siRNA inhibited cell proliferation through 
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induced apoptosis, therefore requiring PRMT4 function to maintain viability53. Gastric 
cancer, lymphoma and leukemia cells show increased levels of PRMT554,55. PRMT5 
interacts with, through the linking molecule AJUBA,  and inhibits the activity of the 
transcription factor SNAIL, a repressor of the oncoprotein E-cadherin, ultimately resulting 
in enhanced cellular proliferation56. 
 Arginine methylation and cardiovascular disease—The free methylarginine 
species ADMA and MMA, but not SDMA, inhibit nitric oxide synthase (NOS), an enzyme 
which generates nitric oxide (NO) which is involved in the cardiovascular, immune, and 
neurological systems14. Free methylarginines are produced by proteolysis of methylated 
proteins and metabolized by dimethylarginine dimethylaminohydrolase (DDAH), creating 
a careful balance of ADMA blood levels. A study, in which DDAH1 knockout mice 
accumulated ADMA and exhibited reduced NO signaling, resulted in impaired vascular 
homeostasis. This indicates that a disruption of the ADMA blood level balance may 
increase risk of cardiovascular disease57. In addition, ADMA levels were elevated in 
cases of atherosclerosis, hypercholesterolemia, and hypertension. Clearly cells need to 
tightly regulate ADMA blood levels, and do this in part using the DDAH enzyme. While 
no studies directly link PRMT regulation to decreased ADMA levels, inhibition of PRMTs 
may be used as an alternative method of ADMA level control, which is one direction the 
medical community could take to regulate ADMA pharmacologically. A cardiology study 
exemplifies this by using the PRMT inhibitor AMI-1 to decrease PRMT1 activity and 
thereby decrease ADMA levels58. Unfortunately, overarching PRMT1 inhibition could be 
detrimental to health because of the scope of arginine methylation throughout the body, 
creating a need for substrate specific and methylation state specific inhibitors. 
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IN-DEPTH BACKGROUND 
Protein Arginine Methyltransferases 
 It should be clear that PRMTs are extremely important enzymes involved in many 
human diseases and biological processes. In order to develop treatments for diseases 
caused by irregular arginine methylation, we need to continue to expand our 
understanding of the PRMT enzymes. The following sections provide important 
background knowledge on the PRMT1 protein structure, the variety of PRMT1 
substrates, and how arginine methylation is regulated. 
 Previous studies show that PRMT1 accounts for approximately 85% of the total 
protein arginine methylation in vivo and is thus a primary subject of study in the field59. 
PRMT1 is known to localize to both the nucleus and the cytoplasm and has a wide 
variety of substrates, a large portion of which are methylated in glycine-arginine rich 
domains60,61.  
 
Structural Insight into PRMT1 
 In order to gain insight into the molecular mechanisms of PRMTs, several crystal 
structures have been solved to date; rat PRMT162, yeast RMT1/Hmt163, rat PRMT364, 
mouse PRMT465, PRMT 5 from Caenorhabditis elegans66, and plant-specific PRMT10 
from Arabidoplis thaliana67. The PRMT structures all exist as homodimers (except 
hexameric Hmt1) with each monomer containing three common elements: an AdoMet 
binding domain partially conserved in other AdoMet-dependent MTases4,11,64,68, a β-
barrel unique to the PRMTs62,64, and a dimerization arm which varies in length (Figure 
2). 
The structure of rat PRMT1 (Figure 1-2) is of particular note because the 
crystallized complex contains a 19 amino acid peptide substrate derived from fibrillarin 
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(R3, GGRGGFGGRGGFGGRGGFG) and the reaction product AdoHcy. This structure 
introduced a picture of the PRMT active site, leading to mutagenic analysis of residues 
interacting with the substrate arginine. The first of these studies by Zhang et al. involves 
two active site glutamates (E144 and E153), coined the “double-E” loop, which stabilize 
the substrate arginine’s guanidine nitrogen via hydrogen bonding62. The importance of 
these glutamates is indicated by their structural conservation in the active sites of all 
solved structures; PRMT1 (E144 and E153), PRMT3 (E326 and E335), CARM1 (E258 
and E267) PRMT5 (E499 and E508), and plant specific PRMT10 (E143 and E152). Site-
directed mutagenesis of theseconserved glutamate residuesshowed that proper 
positioning of the negative charge is essential for catalysis62.  
Figure 2: The crystal structure of rat PRMT1 (PDB:1OR8). Highlighted in the 
structure is SAH (yellow sticks) and arginine (green sticks) in the binding pocket, the 
modeled R3 peptide backbone (green spheres), the dimerization arm (orange), and the 
unique β-barrel (pale yellow).  
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 A second study in the Hevel lab lead by Dr. Shanying Gui, as well as other 
groups, investigated a pair of methionine residues (M48 and M155) in the crystal 
structure of PRMT1 that reside close to the guanidine group of the substrate 
arginine66,69. These methionines are positioned such that they are able to regulate the 
formation of MMA and ADMA in PRMT1 (a type I PRMT) by properly orienting the 
substrate arginine. The M48 equivalent residue in PRMT5 (a type II PRMT) is a 
phenylalanine. Interestingly, a M48F PRMT1 variant gained the ability to produce SDMA. 
These studies show how invaluable structural data is for improved experimental design 
and further understanding of enzyme characteristics. The structures of PRMT1 and 
Hmt1 were essential for my investigations of how oxidation/reduction effects PRMT1 
(chapter 2) and how substrates interact with PRMT1 (chapter 3). 
 
Methylation of PRMT Substrates 
 Understanding specific molecular interactions between PRMTs and substrates is 
important for therapeutical drug design. Identifying these interactions is difficult because 
PRMTs have numerous substrates, many of which contain multiple arginines which are 
selectively methylated. Most PRMTs exhibit a substrate preference in glycine and 
arginine rich (GAR) motifs in either “RGG” or “RXR” sequences. However, substrate 
profiling studies of PRMT1 revealed additional amino acid sequences that expand 
beyond the typical “RGG” model sequence, indicating a wider capability of substrate 
selection by PRMTs70,71.  
 The complexity of arginine methylation is demonstrated by histone proteins, 
which are common substrates for all PRMTs, with methylation observed on histone 3 
(H3) by PRMT412,72, -573,74, and -675 and on histone 4 (H4) by Hmt176,77, PRMT112,33, -278, 
-379, -580, -675,-774, -921, and -1067. Transcriptional regulation is controlled by PTMs on 
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histone tails and PRMTs demonstrate site preferences for methylation of various 
arginines on the histone proteins.  For example, PRMT4 prefers the R17 and R26 
residues of H3 as methylation targets. In vivo, PRMT1 and PRMT5 both target the R3 
residue of H4, introducing ADMA and SDMA respectively. Incredibly, the subtle 
difference(s) between the ADMA and SDMA methylation states lead to opposite 
transcriptional consequences33–36,81. Adding to the complexity, MMA that was previously 
thought to be an intermediate of an ADMA or SDMA end product was shown as an 
active in vivo methylation state at the R2 reside of H3. Incredibly, the ADMA modification 
was shown to have a distinctly different transcriptional output from this newly observed 
MMA methylation state82. It is clear that arginine methylation is extremely complex. 
Unfortunately little is known about the molecular interactions between PRMTs and their 
substrates.  
 
Molecular Interactions between PRMTs and Substrates 
 Structural information typically lends the most clarity to detailed interactions 
between enzymes and their substrate(s) at the atomic level. As previously described, the 
R3 peptide was co-crystallized with the rat PRMT1 enzyme. Unfortunately, data required 
for precise modeling of the R3 peptide was incomplete, likely due to an ability of PRMT1 
to bind the R3 peptide in multiple orientations. This structure of rat PRMT1 with the R3 
substrate bound aligned to the structure of the yeast homologue Hmt1 serves as the 
starting point for enzyme:substrate interaction studies to be discussed in chapter 3. Our 
working hypothesis is that we can restrict the binding mode(s) of the R3 peptide 
substrate to gain further understanding of molecular interactions involved in substrate 
specificity. The broad scope of PRMT’s influences in biological processes indicate a 
great need for inhibitors designed with specificity for a targeted disease state, capable of 
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leaving other processes unhindered. The unveiling of molecular interactions between 
PRMTs and substrates, as well as mechanistic details, aims to lay a foundation for 
isoenzyme specific and/or substrate specific inhibition of PRMTs.  
 
Regulation of PRMTs 
 As with all PTMs, the need to maintain control of signaling is essential. Protein 
methylation is no exception and is carefully regulated by protein interactions, active site 
residues, product inhibition, post-translational modifications, substrate modifications, 
modification removal, and potentially through oxidation/reduction. 
 Regulation by active site residues— Active site residues inherently play a large 
role in overcoming barriers to catalysis. Varying residues in isoenzyme active sites of 
lysine and arginine methyltransferases have been implicated in determining product 
specificity and therefore the biological outputs associated with varied methylation 
states83–87. For example, in the active site of lysine methyltransferases (PKMTs) SET7/9 
and SET8, which only produce monomethyl lysine (MMK), replacement of a conserved 
tyrosine residue with a phenylalanine results in an active site with enough space to 
create di- or trimethyl lysine (DMK or TMK)84,87–90. Previously discussed evidence 
showed that two active site methionines of were at least partially responsible for the 
output of only ADMA by PRMT1 and only SDMA by PRMT566,69. Both PRMT and PKMT 
examples evidence the important role active site residues play in both positioning the 
nucleophilic nitrogen in the correct location as well as sterically regulating dimensions of 
the active site and thus the methylation state of the product. 
 Regulation by protein-protein interactions— Protein arginine methylation can also 
be regulated via protein-protein interactions, resulting in activation, inhibition, or 
modulation of substrate specificity. One clear example of activation through protein-
14 
 
protein interactions is provided by PRMT4, which preferentially methylates free histones 
36-fold higher than nucleosomes. However, when PRMT4 was associated with the 
nucleosomal methylation activator complex (NUMAC), the selectivity of PRMT4 altered 
to preferentially methylate nucleosomal histones 6-fold greater than free histones, a 200-
fold net reversal in specificity91. An example of substrate specificity regulation is provided 
by Cooperator of PRMT5 (CORP5). CORP5 is required to coordinate PRMT5 with 
reconstituted nucleosomes in vitro and results in inhibition ofH3R8 methylation, but not 
methylation of H4R3 or myelin basic protein (MBP), even though all three are known 
PRMT5 substrates92. In vivo, cellular depletion of CORP5 causes loss of PRMT5 
recruitment to the target gene cyclin E1 (CCNE1) on chromatin, correlating to a loss of 
dimethylation at H4R3
92. These studies show that in vivo, PRMT-related biological 
processes can be tuned by regulation of arginine methylation using protein-protein 
interactions. 
 Regulation by PTMs— Post-translational modifications often act as molecular 
switches controlling substrate actions. PRMTs can undergo PTMs which alter activity 
and substrate specificity. One example of enzyme modification is observed in PRMT4 
when Ser217 is phosphorylated. This phosphorylation disrupts Ser217’s hydrogen bond 
with neighboring Tyr154, which is required for AdoMet binding, and consequently 
enzyme activity is squelched93. Recent unpublished studies in the Hevel Lab are 
suggestive of an oxidative modification capable of regulating catalytic activity (chapter 
2). Several published studies have weakly linked increased PRMT-1 expression to 
oxidative stress94–96; however occurrence of a regulatory post-translational oxidative 
modification on PRMTs has not been shown to date. Nevertheless, oxidation as a 
regulatory PTM is not a novel concept and is an emerging field seemingly centered on 
protein tyrosine phosphatases (PTP)97. The widespread incorporation of cysteine 
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residues in many proteins and examples of oxidation/reduction regulating enzymatic 
activity in other fields lend credibility to the idea of oxidative/reductive regulation playing 
a role in the PRMT field. This concept is investigated in Chapter 2 of this thesis. 
 Regulation through substrate modification— In addition to enzyme modification, a 
model for substrate modifications that alter PRMT specificity is provided by histones. 
Histone tails can contain many PTMs, including varied methylation, phosphorylation, 
acetylation, and ubiquitination which make up what is commonly referred to as the 
histone code. Generally the histone code is thought to control chromatin structure 
through protein recruitment; additionally modifications that make up the code can 
regulate further modification. This is evidenced when H3K9 is acetylated and methylation 
of H3R8 by PRMT5 is inhibited
73. Also, the occurrence of H3K4 tri-methylation by an MLL 
complex precludes the occurrence of H3R2 dimethylation by PRMT6 and vice 
versa72,98,99. 
 Regulation by reversing methylation— Post-translational modifications are 
commonly regulated using cellular counter measures. Acetylation and phosphorylation 
are PTMs that are dynamically regulated, serving as on-off switches in many widely 
known pathways, and are unlike methylation signals which are seemingly difficult to 
reverse. The most rapid method of reversing a signal is to remove the PTM that caused 
it. However, methylation was widely considered irreversible until a histone demethylase 
was characterized in 2004100. Methylation of H3K4 has been shown to be removable by 
histone-Lys-specific demethylase (LSD1), requiring the FAD cofactor and generating 
hydrogen peroxide (H2O2) and formaldehyde (CHO) as byproducts. Arginine methylation 
is currently thought to be irreversible, although one study in 2007 identified a Jumonji 
domain-containing 6 protein (JMJD6) which reportedly demethylated H3R2 and H4R3
101. 
Unfortunately, this observation has proven irreproducible in other labs prominent in the 
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methylation field. The crystal structure of JMJD6 was solved in 2010 and structural data, 
supported by mutational studies, suggests thatthe enzyme catalyzes C-5 hydroxylation 
as opposed to N-demethylation102. The combination of lack of reproducibility and 
discovery of an alternative function invokes uncertainty in the existence of an arginine 
demethylase. Consequently, proteolysis of the methylated protein is speculated as the 
predominant method of signal quenching103. 
 Regulation via synthetic small molecule inhibitors— From a medicinal standpoint, 
three mechanisms of pharmacological inhibition that could be used to modulate PRMT1 
activity include; imitating AdoMet, imitating a protein substrate with a peptide mimic, or 
allosterically interfering with substrate binding. Because AdoMet is a widely used 
biological cofactor creating AdoMet analogues, while valuable in vitro, does not have in 
vivo significance as this type of inhibitor may not be solely specific to arginine 
methylation. Creating peptide mimics allows for inhibitor design that potentially 
overcomes the barrier of enzyme specificity, but introduces the common 
pharmacological hurdle of efficient and effective drug delivery. Several inhibitors are 
known which use both these mechanisms and have arginine methyltransferase 
specificity, yet identification of a single PRMT isoform inhibitor continues to be a 
challenge71,104,105. A novel approach to this important problem is to use in silico modeling 
to identify small molecule inhibitors with PRMT isoform, substrate, and methylation state 
specificity. In order for this approach to be taken, a knowledge gap must be closed by 
identifying residues responsible for chemical interactions at the PRMT:substrate 
interface(s), an important goal addressed in chapter 3. 
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CONCLUSION 
 It is evident that arginine methylation by PRMTs is a significant PTM that has 
roles in many essential biological processes. Regulation of such a small but powerful 
modification is critical and several of many methods of control have been reviewed here. 
Identification and understanding of a problem(s) is the first stage and key to discovering 
a solution(s) that correct the problem(s). Similarly, determining the cause of a disease 
and how, in these cases, a causal enzyme(s) functions, sets the stage for researching a 
method to abate or even cure the selected health defect. In order to contribute to this 
field of investigating the biological importance of PRMTs, I have investigated the 
oxidation/reduction of rat PRMT1 (Chapter 2), created a variant Hmt1 library to identify 
enzyme:substrate interactions (Chapter 3), and screened for differences in residual RNA 
levels between wild type and Hmt1-/- yeast cells (Chapter 4). If successful, the short-
term goals of the research at the enzyme characterization stage described in this thesis 
will provide a framework for development of small molecules capable of controlling 
specific interactions of arginine methylation in biological processes important in healthy 
cells. 
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CHAPTER 2 
THE EFFECTS OF REDUCTION ON THE OLIGOMERIZATION, ENZYMATIC 
ACTIVITY, AND SUBSTRATE BINDING OF  
PROTEIN ARGININE METHYLTRANSFERASE 1 (PRMT1) 
 
ABSTRACT 
 Protein arginine methyltransferase 1 (PRMT1) catalyzes the mono- and 
dimethylation of protein arginine residues. Even though arginine methylation occurs on a 
wide variety of protein substrates in many biological processes, regulation of PRMT1 is 
not well understood. We report evidence of oligomeric state, activity, and substrate 
binding differences between oxidized and reduced states of the PRMT1 enzyme. This 
evidence introduces the exciting potential for an in vivo regulatory mechanism of PRMT1 
during oxidative stress. 
 
INTRODUCTION 
 Cellular regulation of the proteome can occur at one of four levels: DNA 
transcription, RNA processing, RNA translation, and post-translational modification 
(PTM). PTMs alter the function of existing proteins, often relaying a signal by inducing 
protein-protein interactions, enhancing or inhibiting enzymatic activity, shifting cellular 
localization, or increasing or decreasing protein stability. Protein methylation, one such 
modification, is the addition of a methyl group to the side chain of specific amino acid 
residues in a protein. Protein arginine methyltransferases catalyze the transfer of a 
methyl group(s) from S-adenosylmethionine (AdoMet) to a guanidinium nitrogen(s) of an 
arginine side chain on a protein substrate, resulting in monomethylarginine (MMA), 
asymmetric dimethylarginine (ADMA) or symmetric dimethylarginine (SDMA). A variety 
of biological pathways1–3 have been associated with arginine methylation and PRMTs 
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are increasingly studied as pharmaceutical targets as methylation continues to be 
implicated in many human diseases4–11. Surprisingly, very little information is available 
regarding how PRMT1 activity is regulated. 
 Using quantitative kinetic and equilibrium measurements as well as gel filtration 
chromatography, we have discovered that PRMT1 is susceptible to oxidative damage 
which can be reversed by reductants such as dithiothreitol (DTT). Reduced and oxidized 
states of PRMT1 have different activities and different oligomeric states.  This work 
highlights the exciting potential that PRMTs are regulated by oxidative stress in vivo. 
 
MATERIALS AND METHODS 
 Materials— S-Adenosyl-L-methionine was purchased from Sigma as a chloride 
salt (≥80%, from yeast).  S-[Methyl-3H]-Adenosyl-L-methionine was purchased from 
Perkin Elmer. The R3 peptide (GGRGGFGRGGFGGRGGFG) was synthesized by the 
Keck Institute (Yale University) and purified to ≥95%. The lyophilized peptide was 
dissolved in water and its concentration was determined by mass or by UV spectroscopy 
(A280 nm=5,690 M
-1cm-1). ZipTip®C4/C18 pipette tips were purchased from Millipore. TEV 
was expressed and purified according to previous protocols12. 
 Plasmid generation—The His6-ratPRMT1 plasmid was previously generated
13. To 
create an enzyme construct with a cleavable His6-tag, a DNA segment coding for a 
tobacco etch virus (TEV) cleavage site was designed with both N- and C-terminal NdeI 
restriction sites. The NdeI restriction enzyme was then used to cut open the vector at an 
NdeI site between the His6-tag and the enzyme coding sequence, and the designed TEV 
insert ligated using the Quick LigationTM kit from New England Biolabs (Cat# 
M2200S).The C101S and C342S variants were generated using the His tagged 
ratPRMT1 (HrP1) plasmid as a PCR template for site directed mutagenesis using the 
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QuikChange Lightning Kit (Stratagene) and sets of complementary oligonucleotide 
primers spanning the desired site of mutation. To create constructs replacing all 11 
cysteine residues with serines, properly coded DNA with N-terminal NdeI and C-terminal 
BamHI restriction sites was ordered from GenScript. The HrP1 (His6-NdeI-ratPRMT1-
BamHI) and HTR (His6-TEV-NdeI-ratPRMT1-BamHI)  vectors as well as the ordered cys 
to ser insert DNA were double digested with NdeI and BamHI restriction enzymes, gel 
extracted from a 0.8% agarose using the Quantum Prep Freeze ‘N Squeeze spin 
columns from Bio-Rad (Cat# 732-6166), and ligated together using the Quick LigationTM 
kit. All plasmids were transformed into a E.coli Dh5α cell line, resuspended in 5 mL liquid 
2XYT culture and grown overnight at 37°C. Plasmids were purified using the Qiagen 
Plasmid Mini Kit (Cat# 12123) and sequenced to confirm the correctness of the open 
reading frame prior to protein expression. 
 Recombinant protein purification— E.coli BL21 cells carrying their respective 
His6-tagged enzyme plasmids were grown in LB broth at 37°C. Protein expression was 
induced at OD 0.6 with 0.5 mM IPTG for 24 hours at room temperature. Cells collected 
via centrifugation were resuspended in wash buffer (50 mM sodium phosphate [pH 7.6], 
and 5 mM (HTR) or 20 mM (HrP1) imidazole). Lysis was performed by sonication in 
three 15-second cycles and the lysate clarified by centrifugation at 47,000xg for 20 
minutes. The resulting supernatant was incubated with 1-6 mL Ni Sepharose 6 Fast Flow 
resin (GE healthcare) rotating for 2 hours at 4°C. The binding reaction was pelleted at 
700xg, the supernatant discarded,  and the resin washed 4 times with 5 mM (HTR only), 
4 times with 20 mM imidazole buffer, 7 times with 70 mM buffer, and lastly eluted in 6 
washes with 250 mM imidazole buffer. The elutions were pooled, buffer exchanged by 
dialysis into storage buffer (50 mM sodium phosphate [pH 7.6], and 10% glycerol), 
concentrated to greater than 2 mg/mL, and beaded in liquid nitrogen for storage at 
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negative 80°C. To generate cleaved constructs, half of the His6-TEV enzymes were put 
into cleavage buffer (50 mM sodium phosphate, 1mM DTT, 2mM EDTA, 5% glycerol), 
the TEV enzyme added (1:10 TEV:enzyme) and allowed to cleave with stirring overnight. 
The cleaved enzyme was dialyzed into storage buffer, re-incubated with nickel resin 
(removal of TEV and remaining His6-tag), and the subsequent supernatant treated the 
same as the His6-tagged elutions.  Enzyme cleavage and purity (>90%) was assessed 
during and after purification using SDS-page. Protein concentrations were determined by 
UV spectroscopy (A280 nm=54,945 M
-1cm-1) and by the Bradford assay with bovine serum 
albumin as a standard. 
 Kinetic assays of PRMT1 constructs— A sensitive methylation assay with 
ZipTip®C4/C18 was used in testing the enzymatic activity under steady-state conditions
12. 
Enzyme activity was assessed at 37 °C in assays containing 100 nM PRMT1 construct, 
2 μM AdoMet (1 μM [3H] AdoMet), 0.38 µM bovine serum albumin, 10 nM MTAN and 
initiated by 200 μM peptide or 2 μM protein substrate. Reactions in the presence of DTT 
were performed by pre-incubation of the reaction with 1 mM DTT for 10 minutes prior to 
reaction initiation with substrate. At different time points, 5 µL samples were removed 
from reactions and stopped in 6 µL of 6 M guanidinium hydrochloride. Samples were 
then processed with ZipTip®C4/C18 pipette tips (for protein or peptide substrates, 
respectively) to separate the unreacted [3H] AdoMet and the radiolabeled product. 
 Size exclusion chromatography— Gel filtration chromatography was performed 
using a Superdex 200 column using a BioLogic LP chromatography system (Bio-Rad). 
The column was equilibrated with 5 column volumes of running buffer consisting of 50 
mM sodium phosphate, 150 mM NaCl, and 5% glycerol. All constructs were analyzed by 
loading 250 µL of enzyme at a concentration of 20 µM and run at 0.4 mL/min for 30 mL. 
An additional HTR sample, using a load concentration of 70 µM, was run to generate an 
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improved chromatogram with a lower background (no change in the peak elution 
volumes was detected). 
 Dissociation Constant Measurement by Intrinsic Fluorescence Quenching—
APC1 fluorimeter (ISS Corp, IL) was used for fluorescence measurements. For the 
AdoMet affinity determinations, an excitation wavelength of 290 nm was used and 
emission spectra were collected at 333 nm. The samples were measured using 1900 uL 
samples containing 1.4 µM PRMT1 in buffer containing 50 mM sodium phosphate, pH 
7.6, and 10% glycerol. Increasing concentrations from 2 to 60 µM AdoMet ligand were 
added in 3-minute intervals.  
 Stopped-Flow Kinetic Measurements— Kinetic data were acquired with an 
AutoSF2000 stopped-flow instrument (Kintek Corp., TX). The stopped-flow system was 
configured with a two-syringe (2.5-mL) kinetic sample handling unit, a 20-μl flow cell 
(with a 10-mm pathlength), and 2.5-mL stop syringe. Temperature control was achieved 
through use of a Neslab RTE-101 water bath. Individual solutions containing 1 µM 
PRMT1 and varied AdoMet concentrations (5-75 µM) were dispensed into the drive 
syringes. Samples were excited at 290 nm and emission was monitored using a 350 nm 
cut-off long pass filter. Data were collected using two time windows (1 sec and 9 sec) 
with 2000 data points collected per window. Data was analyzed with KaleidaGraph 
software using double exponential regression using the equation A1e^(-k1T) + A2e^(-k2T) 
+ C, where A1 and A2 are the amplitudes of the first and second exponential phases and 
k1 and k2 are the rates for the 2 phases. 
 
RESULTS 
The enzymatic activity of PRMT1 is influenced by reducing agents 
 DTT significantly enhances the enzymatic activity of His-rPRMT1— Dithiothreitol 
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(DTT) is a common reducing agent used during purification and/or protein arginine 
methylation assays. Studies using GST-PRMT2 and GST-PRMT7 indicate that DTT 
significantly enhances the enzymatic activity14. Despite wide use and evidence 
suggesting that DTT is required for maximal activity for some of the isoforms, the precise 
effect(s) of DTT on the characteristics of the PRMT1 enzyme remain unclear. To 
rationalize the need for DTT in PRMT1 methylation reactions, we first tested its effect on 
the enzymatic activity of His6-tagged rat PRMT1 (HrP1). Pre-incubation of HrP1 with 1 
mM DTT increased methyl transferase activity by 13-17-fold with the R3 peptide 
substrate (Figure 2-1A), and by 5-fold with the HnRNP K protein substrate (data not 
shown). 
 In order to better understand how DTT increased enzymatic activity, we pre-
incubated PRMT1 with DTT and removed the DTT using a desalting column prior to the 
methyltransferase reaction. The activity of the desalted HrP1 with the R3 peptide only 
increased by 2-fold (Figure 2-1A), which demonstrated that the effect of DTT was 
transient. Next we investigated the relationship between enzymatic activity and the 
concentration of DTT. Methylation assays were performed with varied concentrations of 
DTT ranging from 0.1 mM to 5 mM and a maximal rate enhancement at 1.5-2mM DTT 
(apparent kcat = 1.91 min
-1) was observed (Figure 2-1B). 
Maximum PRMT1 activity requires a reductant— DTT has two potential methods 
of action to increase PRMT1 activity: acting either as a reductant or as an intermediate 
acceptor molecule in the methyl group transfer process. Methylation of the sulfhydryl 
groups in DTT was previously observed with small molecule plant O-
methyltransferases15. Even though no DTT methylation was detected in our no substrate 
control reaction (Figure 2-1A), we further tested this hypothesis by replacing DTT with an 
alternative thiol-free reductant, Tris(2-carboxyethyl)phosphine (TCEP). HrP1 activity was 
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examined using 1mM TCEP and the R3 peptide substrate and the rate enhancement 
observed was identical to that observed using 1mM DTT. We conclude from this study 
that DTT is acting as a reductant and not acting as a methyl group transfer intermediate. 
 
The PRMT core is responsible for the reductant dependent activity increase 
 DTT increases the activity of both His6-tagged and un-tagged PRMT1 enzymes— 
Several different affinity tags are used for PRMT1 purification and variable methylation 
rates have been observed16–18. We questioned whether the His6-tag was influencing our 
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Figure 2-1: The effect of reducing agents on the enzymatic activity of PRMT1. (A) 
HrP1 methylation rates assayed in the absence () and presence of DTT () or TCEP 
() and after desalting following a 10-minute pre-incubation with DTT (). A control 
reaction with no substrate was also run (). (B) The apparent kcat measured as a 
function of DTT concentration. (C) Structures of DTT, TCEP, and S-adenosyl 
methionine. (Note, this work has previously appeared as part of Shanying Gui’s Ph.D. 
dissertation). 
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observed rate changes upon adding DTT. We created a His6-tagged, tobacco etch virus 
(TEV) cleavable, rat PRMT1 construct (HTR) in order to purify a cleaved, and therefore 
un-tagged enzyme (cHTR), for kinetic analysis with DTT. Attempts to express a tagless 
version of PRMT1 resulted in unstable protein which lost activity rapidly (data not 
shown). Several biological replicates of HTR and cHTR all exhibited the observed 
enzymatic rate enhancement upon the addition of 1mM DTT (Figure 2-2). 
 Incubation with DTT and EDTA is responsible for improved cHTR activity— The 
protocol for TEV cleavage included 1mM DTT and 2 mM EDTA present in the dialysis 
buffer during the overnight cleavage process. We surmised from this that the lessened 
DTT effect on cHTR activity was likely due to the overnight dialysis during cleavage, and 
the subsequent purification, removing DTT, allowed only a small amount of oxidation to 
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Figure 2-2: The effect of DTT is independent of the His6-tag. Enzymatic activity of 
HTR, cHTR, and dialyzed HTR assayed with the R3 peptide substrate in the absence 
(, , )  and presence of DTT (, , ) respectively. 
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occur prior to storage. To test this theory, we again purified both the HTR and cHTR 
enzymes and treated the HTR enzyme to same overnight dialysis step cHTR received. 
Methylation assays of these newly purified HTR and cHTR enzymes revealed no 
significant rate enhancement upon addition of DTT (Figure 2-2). We conclude from 
experiments thus far that PRMT1 is susceptible to reversible oxidative impairment, 
independent of the His6-affinity tag. 
 
Reduction with DTT alters the oligomeric state of PRMT1 
 Feng et al.16 introduced the idea that changing the oligomeric state of PRMT1 
affects enzymatic activity. Since PRMT1 reduction results in increases in activity, we 
hypothesized that the reductant may be changing the oligomeric state of the enzyme. 
We assessed our hypothesis using size exclusion chromatography pre- and post-
reduction of the enzymes (Figure 2-3). Unreduced HTR migrates over a broad range of 
oligomeric states, with the majority of the protein existing in oligomers that migrate at 
molecular weights above 660 kDa. As a reference, PRMT1 is thought to be active as an 
80 kDa dimer at minimum17. Overnight incubation with 1mM DTT resulted in a shifting of 
oligomeric states, with the majority of oligomers migrating below 660 kDa. Addition of 
2mM EDTA to the overnight DTT incubation resulted in a much greater shift towards a 
homogeneous oligomeric state migrating between 350 and 450 kDa. The cHTR enzyme 
migrated as two peaks, a small void volume peak, and a large peak at roughly the 
samemigration volume as the shifted HTR peaks. Additionally, overnight treatment of 
cHTR with 1mM DTT had no detectable effect on the migration of cHTR. The general 
decrease in siz e in the presence of a reductant, combined with the previously discussed 
activity data, suggest that the oligomeric differences between HTR and cHTR are not 
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due to the His6-tag, but due to cHTR’s treatment in overnight dialysis in the presence of 
DTT/EDTA during the cleavage process. 
 
The reductant-dependent effects on PRMT1 require a cysteine(s) residue 
C101 and C342 are not responsible for reductive effects— The most common 
mechanism for oxidative damage is the oxidation of cysteine residues. As such, we 
began our investigation into what residues of the PRMT core are undergoing redox 
chemistry by mutating cysteines. To select cysteines for mutation, we searched the rat 
PRMT1 crystal structure (see Figure 2-8) for cysteine residues capable of undergoing 
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Figure 2-3: Oligomeric state assessment via size exclusion chromatography. 
(A) HTR in the absence of DTT, (B) HTR incubated overnight with 1mM DTT, (C) 
HTR incubated overnight with 1mM DTT and 2mM EDTA, (D) cHTR in the absence 
of DTT, (E) cHTR incubated overnight with 1mM DTT and 2mM EDTA. Molecular 
weight standards: 660kDa (1) 440kDa (2), 200kDa (3), and 66kDa (4). 
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oxidation and found that cysteines 101, 208, 232, 254, 342, and 346 are all solvent 
accessible. Cysteine 101 resides on the far edge of the AdoMet binding pocket and 
directly interacts with the adenine ring structure of AdoMet. A recent quantitative 
reactivity profiling study identified C101 as hyper-reactive with 4-hydroxyl-2-nonenal 
(HNE)19, indicating that C101 may be prone to oxidation. Surprisingly, mutation of C101 
to serine results in a construct mimicking wild type activity, including the response to 
DTT (Figure 2-4). Closer evaluation of our rat PRMT1 M48L crystal structure showed 
increased electron density around cysteine 342, suggesting possible oxidation of the 
thiolate moiety to a reducible sulfenate. Although this residue is relatively removed from 
the active site, it has been suggested that residues distant from the active site can 
regulate PRMT substrates specificity20. The C342S variant also mimicked wild type 
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Figure 2-4: Enzymatic activity of single cysteine variants with the R3 peptide 
substrate. C101S and C342 assayed in the absence (,) and presence of DTT 
(,) respectively.  
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enzymatic activity, including the DTT enhancement (Figure 2-4A). The similarities 
between the wild type enzyme and C101S/C342S variants indicate that neither is 
culpable for the effects caused by oxidation/reduction. 
 Mutation of all cysteine residues in the PRMT1 enzyme negates the DTT effect—
We took a broader approach to evaluate whether any cysteine residues were 
responsible for the effect of oxidation/reduction and expressed both cleavable and un-
cleavable cysteine to serine variant rat PRMT1 enzymes (HTRcys- and HrP1cys-). The 
His6-tagged and cleaved enzymes were assayed with the R3 peptide and exhibited no 
enhanced activity upon pre-incubation with DTT (Figure 2-5A). In addition to activity 
measurements, the oligomeric state was assessed by size-exclusion chromatography 
Figure 2-5: Enzymatic activity and oligomeric state of the cysteine to serine 
PRMT1 variant enzymes. (A) Enzymatic activity of HrP1cys-, HTRcys-, and cHTRcys- 
with the R3 substrate assayed in the absence (, , ) and presence of DTT (, , 
) respectively. (B) Size exclusion chromatography comparing cHTR (A) and HTRcys- 
(B). Molecular weight standards: 660kDa (1) 440kDa (2), 200kDa (3), and 66kDa (4). 
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(Figure 2-5B). The cysteine-less PRMT1 variants all exhibited migration patterns similar 
to that of the maximally active cHTR and HTR (pre-incubated with DTT). We conclude 
from these observations that one (or more) cysteines are involved in the redox chemistry 
causing increased activity after incubation with a reductant. 
 
AdoMet shows moderately increased binding affinity for PRMT1 in the presence of 
DTT  
 The dissociation constant (Kd) is mildly decreased by reduction— After using 
steady state kinetics to identify that a cysteine residue(s) was responsible for the overall 
effect of DTT on enzymatic activity, we sought to elucidate details of the kinetic 
mechanism of PRMT1 that are affected by reduction. We proceeded to determine the 
dissociation constant (Kd) of AdoMet for PRMT1 by using a previously derived procedure 
to measure intrinsic tryptophan fluorescence quenching of PRMT1 upon the addition of 
ligand. The Kd values of AdoMet for HTR in the absence and presence of DTT were 
similar (1.7-fold greater in the absence of DTT, Figure 2-6) but not different enough to 
explain our observed changes in enzymatic activity. 
The association constant of AdoMet for PRMT1 is dramatically increased in the 
presence of DTT— The intrinsic fluorescence quenching experiment measures the Kd of 
AdoMet for PRMT1 at equilibrium. Previous attempts to determine the binding rate 
constant of AdoMet to the un-cleavable His6-tagged ratPRMT1 enzyme proved 
unsuccessful in the absence of DTT. This inability to collect usable data combined with 
the slight increase in Kd in the presence of DTT prompted us to investigate if DTT was 
affecting the rate at which AdoMet binds to PRMT1. Using a more sensitive stopped-flow 
fluorimeter we were able to collect fluorescence quenching data with HTR both in the 
absence and presence of DTT (Figure 2-7A). Interestingly, addition of DTT to the 
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reactions resulted in additional fluorescence quenching. These quenching curves were 
fit using double exponential regression to calculate k1 and concentration of AdoMet (µM) 
vs. k1 (s
-1) was plotted (Figure 2-7B). This plot shows that the average association 
constant of AdoMet for PRMT1 is 21-fold faster in the presence of DTT. While the rate of 
AdoMet binding to PRMT1 is still faster than the reported methyl transfer step, it may still 
act in a combinatorial fashion with other reaction steps which result in the slowed overall 
reaction rate (kcat) we observe under steady state conditions when the enzyme becomes 
oxidized. 
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Figure 2-6: The effect of DTT on the dissociation constant (kd) of AdoMet for 
PRMT1. Fluorescence quenching of HTR in the absence () and presence () of DTT. 
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DISCUSSION 
 Our understanding of the importance of PRMTs in biology and human disease 
has greatly increased during the past decade. Arginine methylation has been observed 
in cardiovascular disease21–23 and cancer8,24–29 suggesting PRMTs as a good target for 
therapeutic drug development to treat disease. Regulation of enzymatic activity is 
essential for proper functioning of cellular processes. Protein methylation is carefully 
regulated by protein interactions30–33, active site residues17,34,35, product inhibition36, and 
post-translational modifications37,38. In this work, we demonstrate changes in quaternary 
structure and enzymatic activity in reductive conditions, thereby suggesting a potential 
mechanism of regulation during oxidative stress in vivo. 
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Figure 2-7: The effect of DTT on the on and off rates of AdoMet binding to 
PRMT1. (A) Stopped-flow fluorescence quenching of HTR by 0 (grey) and 10 µM 
(colored) AdoMet in the absence (blue) and presence (red) of DTT. Traces of a buffer 
only sample (lightest grey) and the two HTR samples with 0 µM SAM all overlay and 
are colored grey for clarity. (B) Plot of the varied AdoMet concentration vs. the 
calculated k1 (on rate) of AdoMet to HTR in the absence () and presence () of DTT. 
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 The enzymatic activity and oligomeric state of PRMT1 are changed by 
reduction— The quaternary structure of PRMTs as it relates to enzymatic activity has 
been a source of great study in the PRMT1 field and it is accepted that PRMT oligomers 
are required for enzymatic activity17,39,40. Feng et al.16 used chemical crosslinking to 
investigate the effect of enzyme concentration on oligomeric state. Using a concentration 
range of 0.012 µM to 1.56 µM enzyme, an overall increase in oligomeric state was 
observed as concentration increased. More specifically, the quantity of mono- and di-
mers decreased while the quantity of oligomers increased, causing an oligomeric 
rearrangement which slowed at ~0.5 µM enzyme.  
At first, our studies showing that reducing PRMT1 decreased the overall 
oligomeric mass and increased enzymatic activity may seem to conflict with this previous 
study. However, our oligomeric state studies are performed at a concentration above the 
observed maximal transition state, and our size-exclusion chromatography observations 
showed that the reduced PRMT1 enzyme corresponded to a molecular weight range 
(120-450 kDa) similar to other in vitro and in vivo studies17,26,41. Upon closer examination 
of the western blot performed by Feng et al.16, it is observed that there are oligomeric 
states ranging from monomers at 42 kDa to molecular weights greater than hexamers at 
250 kDa. Ultimately, our work is consistent with previous observations that a higher 
order oligomeric state is required for optimal enzymatic activity, not to be confused with 
the massive oligomeric state observed in oxidative conditions. In addition to the previous 
observations, we show evidence, through our work in non-reducing and reducing 
environments, that this dynamic and complex system has great potential to be regulated 
by oxidative stress in vivo. 
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 Cysteine oxidation/reduction regulates PRMT activity in vitro—Cysteine residues 
contain a thiol moiety in their side chain well known to undergo oxidation and reduction 
in physiological conditions. At lower concentrations, reactive oxygen species can behave 
as signaling molecules, and have been shown, through protein cysteine 
oxidation/reduction, to promote both cell proliferation42 and apoptosis43. Of the 11 
cysteine residues found in PRMT1, six are solvent accessible in the rat PRMT1 structure 
(Figure 2-8) and therefore have the potential for participating in redox chemistry. 
C254 
C342 
C101 
C345 
C208 
C232 
Figure 2-8: The structure of the rat PRMT1 enzyme. PDB:1OR8 Highlighted are the 
six solvent accessible cysteine residues (green), the three buried cysteine residues 
(red), the product SAH (yellow), the PRMT1 enzyme (grey), and a surface 
representation of the second monomer (light blue). 
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Unfortunately, the two cysteine residues we selected, C101 and C342S, were not 
responsible for changes in activity and oligomeric state. However, we have shown 
through the use of cysteine-less PRMT1 enzymes, which have approximately half of wild 
type activity but no longer respond to reduction, that a cysteine residue(s) is responsible 
for the observed redox effects. To address what type of cysteine oxidation is responsible 
for the observed effects, we first observed from the crystal structure that the only 
cysteine likely to hinder AdoMet binding was C101, due to its proximity to, and direct 
interaction with, the benzene ring in the adenosine portion of the molecule. Since C101S 
is still redox sensitive, we propose that the oxidization is most likely a disulfide bond 
formation, possibly at C254, as opposed to formation of a sulfenic, sulfinic, or sulfonic 
acid moiety on the thiol group of a cysteine residue side chain. Cysteine 254, observed 
as a disulfide between dimers in the rat PRMT1 crystal structure, was previously 
mutated to alanine to assess the relevance of the disulfide bond. Both oligomeric state 
and activity were similar when comparing the wild type enzyme to the C254A variant. In 
retrospect however, the C254 residue still seems like a likely candidate for 
oxidation/reduction chemistry because the C254A experiments were conducted in the 
presence of a reductant, masking any potential oxidative effect that may have been 
observed.  
 Oxidation and reduction is a potential regulator of the rate limiting step in PRMT1 
methylation— Understanding the mechanism of PRMT1 has been the work of several 
groups16,44,45. Feng et al.16 reports that methyl transfer is the rate limiting step of the 
PRMT1 mechanism (in the presence of DTT). Our enzyme as expressed and purified 
over nickel resin, devoid of any DTT, may mimic an enzyme which has undergone mild 
in vivo oxidative stress conditions. PRMT1 prepared in these in vitro conditions exists in 
a state in which the rate of AdoMet binding is impaired greater than 20-fold. While the 
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rate of AdoMet binding to PRMT1 (>5.8 s-1) is still faster than the reported methyl 
transfer step (0.022 s-1), it may be that DTT induces rate differences in other steps of the 
mechanism, including methyl transfer. 
 
CONCLUSION 
 Our data, combined with other studies, indicates that oxidative stress conditions 
may, through a cysteine oxidation, restructure PRMT1 into an unordered, massive 
oligomeric state with an impaired ability to efficiently bind AdoMet. Furthermore, PRMT1 
activity, in a state where AdoMet binding is rate limiting, will be more susceptible to 
changes in cellular concentrations of AdoMet. 
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 Protein arginine methylation is an abundant post-translational modification 
catalyzed by protein arginine methyltransferases (PRMTs). Arginine methylation plays 
important roles in a variety of cellular pathways and human diseases. PRMT1, the 
predominant PRMT, catalyzes approximately 85% of all protein arginine methylation in 
vivo. While many details of how PRMT1 functions have been uncovered through the 
past two decades, there are many details which remain unclear, including how arginine 
methylation is regulated, how PRMT1 binds substrates, and what role PRMTs play in 
RNA surveillance. Our recent data presented in this thesis showed that reduction of the 
PRMT1 enzyme, following recombinant expression and purification, changes both 
enzymatic activity and oligomeric state. A cysteine residue(s) was found to be 
responsible for the observed redox chemistry in PRMT1 and at least one parameter in 
the kinetic mechanism, S-adenosylmethionine (AdoMet) binding, was faster with a 
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reduced enzyme. This work suggests exciting potential for the regulation of PRMTs in 
vivo by oxidative stress. 
 In addition to studying the effects of reduction/oxidation on PRMT1, a foundation 
for future experiments was laid. These experiments investigate substrate recognition by 
PRMTs and what the role arginine methylation may play in RNA processing and 
surveillance. To better understand how PRMTs selectively bind a wide variety of 
substrates, I have designed and preliminarily characterized several Hmt1 (the S. 
cerevisiae homologue of PRMT1) variants. These variants will be used for crystallization 
trials of a homogeneous complex, containing Hmt1, AdoMet, and a peptide substrate, 
capable of revealing specific chemical interactions between Hmt1 and the peptide 
substrate. To further our understanding of Hmt1’s role in RNA processing and 
surveillance, particularly in RNA degradation pathways, I extracted yeast RNA from both 
wild type and Hmt1-null cells. The RNA was probed using a S. cerevisiae whole-genome 
microarray. This analysis revealed that Hmt1 exhibits statistically significant effects in 
several broad areas including molecular function, biological processes, cellular 
components, and some KEGG pathways. The presented studies have revealed the 
exciting potential for an in vivo regulatory mechanism of PRMT1 and each study is 
primed for further investigation both in vivo and in vitro. 
(85 pages) 
CHAPTER 3 
IDENTIFICATION AND CHEMICAL CHARACTERIZATION  
OF THE BINDING INTERFACE(S) BETWEEN  
hnRNP METHYLTRANSFERASE 1 (Hmt1) AND ITS SUBSTRATES 
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INTRODUCTION 
 Cellular communication is essential for life. One way cells communicate is 
through post-translational modifications. Protein arginine methylation has become a 
prominent player in signal transduction and protein regulation in eukaryotic cells1–8. 
There are 9 PRMTs that catalyze arginine methylation, using S-adenosylmethionine 
(AdoMet) as a methyl donor, to form monomethylarginine (MMA), asymmetric 
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) on protein substrates. 
Type I PRMTs represent the majority of methyltransferases and are capable of 
catalyzing MMA and ADMA formation. Type II PRMTs produce both MMA and SDMA, 
and type III PRMTs produce only MMA. Which form of arginine (MMA, ADMA, SDMA) is 
produced has the potential to yield significant differences in biological response9–11.  
 These differing responses indicate that controlling arginine methylation, like other 
post-translational modifications such as phosphorylation, is important for proper cellular 
function. The methods of control include substrate specificity, the type of methylation 
(MMA, AMDA, and SDMA), and the amount of methylation. While the mechanism of 
PRMTs has been studied, there is a substantial lack of information explaining how 
PRMT targets are recognized. In Saccharomyces cerevisiae, the human PRMT1 
homologue hnRNP methyltransferase 1 (Hmt1), plays a role in regulating RNA-binding 
proteins during the metabolism of nuclear pre-mRNA12. In addition to understanding how 
methylation functions in biological pathways, enzyme specific and substrate specific 
inhibitors for PRMTs will be of great value to the medical community in treating 
conditions and diseases such as several types of cancer, muscular dystrophy, 
amyotrophic lateral sclerosis (ALS), cardiovascular disease, diabetes mellitus, kidney 
failure, chronic pulmonary disease, coronary heart disease, and renal failure13. 
 Inhibitors of PRMT1 can imitate AdoMet (cofactor), imitate a protein substrate, or 
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interfere with substrate binding. AdoMet is a widely used biological cofactor, thus 
creating AdoMet analogues, while valuable in vitro, may have limited in vivo significance 
as this type of inhibitor is likely lack specificity for arginine methylation alone. Creating 
peptide mimics overcomes the barrier of enzyme specificity, but introduces the common 
hurdle of efficient and effective drug delivery. Several inhibitors are known which use 
both these mechanisms and have arginine methyltransferase specificity, yet 
identification of a single PRMT isoform inhibitor continues to be a challenge14,15,16. A 
novel approach to this important problem is to use in silico modeling to identify small 
molecule inhibitors that would block substrate binding at a site other than the active site. 
It is expected that this type of inhibitor would not only show isoform specificity, but also 
block the methylation of specific protein substrates. In order for this approach to be 
taken, a knowledge gap must be closed by identifying residues responsible for chemical 
interactions at the PRMT:substrate interface(s).  
Even with several solved PRMT crystal structures, one of which includes a bound 
peptide substrate (a fibrillarin mimic, R3), the molecular mechanism(s) by which PRMTs 
recognize their substrates remains unclear17,18. This lack of clarity stems from difficulty 
obtaining crystals for structural analysis and from poor electron density data of the 
bound peptide substrate in the crystal structure. In the rat PRMT1 structure, the electron 
densityor the enzyme is clear, with exception of the N-terminal 40 amino acids which 
appear mobile across all PRMT structures; however only electron density for the 
backbone of the peptide substrate is visible. To add to the confusion, there is electron 
density for the peptide backbone in three locations, or grooves, indicating multiple 
substrate binding modes (Figure 3-1). In order to elucidate chemical interactions 
between peptide substrate and enzyme, we are combining surface mutagenesis in the 
grooves with carefully constructed asymmetric peptide substrates to create an 
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enzyme:substrate complex that is sterically forcedinto a single homogeneous 
conformation (Figure 3-1). My work has yielded eight purifiable variant Hmt1 proteins, 
and preliminary enzymatic activities of all nine enzymes (variants and wild type) with 
each of the three asymmetric peptides, are presented. 
 
MATERIALS AND METHODS 
 Mutagenesis and purification—The pET15b vector coding for His6-tagged WT-
Hmt1 expression was used as a template for site-directed mutagenesis with the 
Figure 3-1: Depiction of four possible HMT1:peptide binding modes. (A) A top 
down view of HMT1 crystal structure with the R3 peptide superimposed from the rat 
PRMT1 structure. Note, only four of ten possible binding modes are shown.Grey, 
HMT1, Yellow, S-adenosylhomocysteine (AdoHcy), Red, R3 peptide backbone as 
spheres, active site arginine as sticks. (B) Cartoon of HMT1 and the R3 peptide 
bound with the central arginine in the active site (C) HMT1 with the N-terminal R3 
arginine in the active site. (D) HMT1 with the c-terminal R3 arginine in the active site. 
(E) Alternative binding of HMT1 with the c-terminal R3 arginine in the active site.  
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QuikChange Lightning Kit (Stratagene) and sets of complementary oligonucleotide 
primers spanning the 8 desired sites of mutation. After PCR, the plasmids were 
transformed into a E.coli Dh5α cell line, resuspended in 5mL liquid 2XYT culture and 
grown overnight at 37°C. Plasmids were purified using the Qiagen Plasmid Mini Kit 
(Cat# 12123) and sequenced to confirm the correctness of the open reading frame prior 
to protein expression. The His6-tagged WT-Hmt1 enzyme and all eight variants were 
purified as described in Chapter 2.  
 Kinetic assays of Hmt1 constructs— A sensitive methylation assay with 
ZipTip®C4/C18 was used in testing the enzymatic activity under steady-state conditions
19. 
Catalytic activities were assessed at 37 °C in assays containing 100 nM PRMT1 
construct, 2μM AdoMet (1 μM [3H]AdoMet), 10 mM MTAN and initiated by 200 μM of the 
peptide substrates (R3, RKK, KRK, or KKR). At different time points, 5 µL samples were 
removed from reactions and stopped in 6 µL of 6 M guanidinium hydrochloride. Samples 
were then processed with ZipTip®C4/C18 pipette tips (for protein or peptide substrates, 
respectively) to separate the unreacted [3H] AdoMet and the radiolabeled product. 
 
RESULTS AND DISCUSSION 
Creating tools to investigate molecular interactions 
 Hmt1 variant design— In order to investigate how PRMTs target substrates, we 
need to identify the surface(s) and residues involved in the enzyme:substrate interface. 
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We decided to approach this problem using site-directed mutagenesis and three 
asymmetric peptide substrates to limit peptide binding to a single mode. To begin design 
of the Hmt1 variants, we first aligned the crystal structure of PRMT1 containing the 
partial density of a bound peptide (R3) (PDB ID: 1OR8) with the crystal structure of Hmt1 
(PDB ID: 1G6Q). The R3 peptide backbone was then modeled onto the Hmt1 structure. 
When selecting residues for mutagenesis we took into account residue conservation 
between rat PRMT1 and yeast Hmt1, residue charge, and side chain size (Figure 3-2). 
Residue conservation is an important selection tool because rPRMT1 and Hmt1 are 
capable of sharing cross species protein substrates. Residue charge was used to select 
 
A B 
C 
 
Figure 3-2: Considerations for residue 
selection for mutagenesis. (A) HMT1 
with the R3 peptide (green) and bound 
SAH (yellow),  modeled on top of the 
enzyme’s electrostatic surface. (B) 
Outward facing resides (red) in binding 
groove one of Hmt1 (light grey) to be 
considered for size. (C) Conservation in 
putative peptide binding groove one, 
where red residues are strictly 
conserved, pink are slightly conserved 
and cyan residues are un-conserved. 
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residues in order to interrupt potential ionic interactions. Small side chain residues along 
the bottom of the groove were chosen as targets to increase the side chain size and 
thereby sterically hinder peptide binding.  
 The residues selected include: T40Y and V41E, to change a small hydrophobic 
residue into a large polar/charged residue; D145G, to eliminate a negative charge that 
may interact with positive residues in the peptide; D145W, to eliminate charge and 
sterically block the binding to groove 1; N320A, assessing the importance of the only 
conserved residue in groove 2; D152A, again eliminating a negative charge possibly 
interacting with the peptide; and lastly, D152K, to reverse the potentially interacting 
negative charge. 
 Asymmetric peptide design— Three peptides (RKK, KRK, and KKR, see Table 3-
1) were strategically designed from the R3 peptide sequence, a mimic of the native 
protein substrate fibrillarin20,21. In these peptides, two of the three arginines were 
removed and the remaining arginine was positioned in three locations relative to the N-
terminus of the peptide. This design creates three peptides that are asymmetric and 
unidirectional. Our working hypothesis is that Hmt1 can only bind peptides in a 
unidirectional orientation. In combination with mutations to block peptides from binding in 
Peptide Name Peptide Sequence 
R3 (RRR) AcGGRGGFGRGGFGGRGGFG 
RKK AcGGRGGFGKGGFGGKGGFG 
KRK AcGGKGGFGRGGFGGKGGFG 
KKR AcGGKGGFGKGGFGGRGGFG 
Table 3-1: Sequences of the designed peptide substrates. 
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different grooves, we hope to uncover a variant/peptide combination capable of 
homogenous crystallization which should reveal specific molecular interactions between 
the peptide and Hmt1. 
 
Comparing wild type Hmt1 to variant Hmt1 activities  
Our hypothesis— Our first method of identifying which Hmt1 variants may be of 
use in crystal structure trials is to assess the enzymatic activity with the asymmetric 
peptides. In theory, if peptides do bind in multiple modes, each variant should be 
capable of methylating the R3 peptide. Variants which lack the ability to methylate R3 
indicate either acomplete loss of enzymatic activity and/or improperly folded protein,and 
while not useful for this enzyme:substrate interaction study, these variants will identify 
important residues for protein structure stability and/or catalysis. Our goal is to uncover a 
combination of variants, in different grooves, which methylate the R3 peptide, but exhibit 
inhibited methylation of only one of the asymmetric peptides. Take for example, a 
scenario in which a mutation in groove 1 allows methylation of all the peptides except 
RKK, and a mutation in groove 3 allows methylation of all the peptides except KKR. 
These two mutations could then be combined in a double variant which blocks binding of 
peptides in both groove 1 and groove 3. We would thus expect this double variant to 
only methylate the R3 and KRK peptides, implying formation a single binding mode. This 
double variant and the R3 and/or KRK peptides could be put into crystal trials, expecting 
that the increased homogeneity of the complex would result in a structure that reveals 
detailed atomic contacts between the enzyme and peptide substrate. 
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Preliminary enzymatic activity screening— Initially, wild type Hmt1 and each of 
the eight variants were purified and assayed with R3 and RKK (Figure 3-3). Additionally, 
Hmt1 and five variants (D152A, D152K, N302A, T40Y, and V41E) were purified again 
and assayed in duplicate with all four peptides (R3, RKK, KRK, and KKR) (Figure 3-3). 
Unfortunately many purifications of the wild type Hmt1 enzyme have resulted in varied 
enzymatic activities. This lack of repeatability in wild type activity makes comparison of 
each variant to wild type difficult. The wild type-enzyme only weakly methylates the RKK 
or KRK peptide substrates, but it is unclear if this lack of activity is due to substrate 
preference or to preparative issues. Due to time constraints and thus a lack of a 
complete data set, there are not yet any apparent combinations of variants of which a 
double variant can be created. The V41E variant has very low activity with all the 
peptides, indicating that the larger charged residue change is disrupting turnover. The 
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Figure 3-3: Enzymatic activities of the wild type and variant Hmt1 enzymes. 
Enzymes were assayed with all four peptides: R3 (red), RKK (blue), KRK (green), 
and KKR (grey). 
58 
 
D145Y variant exhibited enzymatic activity 2- to 50-fold greater than the other variants 
with the R3 and RKK peptides and would be a good variant to assay with KRK and KKR 
to test for a loss of activity. 
 Inconsistent wild type activity needs to be corrected— Before proceeding with 
additional experiments investigating these variants, the variation in wild type Hmt1 
enzymatic activity needs to be eliminated. A recent study revealed that Hmt1 can be 
phosphorylated in vivo, on serine 9, and that this event is required for oligomerization 
and activity22. They also observed that mutation of serine 9 to glutamate (S9E) mimics 
phosphorylated enzyme and restores oligomerization and activity in vivo. The unknown 
phosphorylation state of serine 9 may be one contributing parameter to the observed 
inconsistency in Hmt1 enzymatic activity. In order to address this inconsistency, we need 
to generate a S9E variant in our lab and assess its in vitro enzymatic activity. If multiple 
purifications of the S9E variant yield consistent enzymatic activity, I would recommend 
this mutation to be made on each of my variants in order to better mimic in vivo 
conditions and make wild type Hmt1 more comparable with the variant enzymes. 
Unfortunately, until this wild type issue is resolved, the usefulness of the current 
mutations is limited and no significant conclusions have been drawn. 
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CHAPTER 4 
WHOLE GENOME MICROARRAY ANALYSIS OF TOTAL 
RNA LEVELS IN WILD TYPE AND Hmt1-Null S. Cerevisiae CELL LINES 
 
INTRODUCTION 
 RNA binding proteins (RBPs) are critical to the success of many steps of RNA 
processing. Many of these proteins undergo post-translational modifications (PTMs), 
such as phosphorylation and methylation, which may regulate their interactions with 
RNA. In Saccharomyces cerevisiae, hnRNP methyltransferase 1 (Hmt1) mediated 
methylation has been shown to be important in RNA surveillance and transport1–4. The 
hnRNPs nuclear protein localization 3 (Npl3), heterogeneous nuclear ribonuclear protein 
1 (Hrp1), and nuclear polyadenylated RNA binding 2 (Nab2) are all RBPs involved in 
RNA transport and are methylated by arginine methylation implicating Hmt1 as one 
mechanism of regulating RNA export5–7. In addition to export, RNA can be tagged for 
degradation by the addition of a short poly(A) tail to the 3’ end. A poly(A) polymerase 
(Trf4 or Trf5), a putative RNA-binding protein (Air1 or Air2), and a helicase (Mtr4) make 
up the TRAMP complex which identifies RNA substrates and applies poly(A) tails8. The 
TRAMP complex acts on a wide range of substrates including tRNAs, snoRNAs, 
snRNAs, ncRNAs, rRNAs, some mRNAs, and cryptic unstable transcripts9. The Air1 and 
Air2 proteins bind Hmt1 and inhibit its activity, possibly regulating RNA transport through 
regulation of the RBPs10. The association of Air1 or Air2 with Hmt1 introduces the 
concept of a role of arginine methylation in RNA processing on non-coding RNAs 
(ncRNA). 
 To further understand the role of arginine methylation in global RNA surveillance, 
we sought out exploratory techniques capable of monitoring RNA levels. A previous 
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systems biology approach was taken to study Hmt1’s role in the genome-wide 
localization profiles of its substrates. During this study, wild type (Hmt1) versus Hmt1-
null (Hmt1-/-) yeast cells were examined for changes in global mRNA levels analysis 
with a full-length cDNA microarray1. Interestingly, gene expression of 64 genes was 
altered greater than 2-fold by the loss of Hmt1. A separate study investigating the role of 
the exosomal proteins Lrp1 (Rrp47) and Rrp6 (an exonuclease) in genome-wide mRNA 
degradation used the transcriptional inhibitor thiolutin to halt RNA production in wild type 
(Lrp1) and Lrp1-null (Lrp1-/-) yeast cells11. After thiolutin treatment, the RNA already 
produced is given to 45 minutes degrade, then the RNA abundance changes (wild type 
vs Lrp1-null) are assayed using a whole-genome microarray, which changes directly 
reflect changes in RNA degradation due to the absence of the Lrp1 gene. We reasoned 
that we could expand upon the current data, which reflects the loss of Hmt1 on mRNA 
under equilibrium conditions, by combining these two techniques. In addition, because of 
Hmt1’s known associations with many proteins involved in RNA surveillance and 
transport, we adapted our reverse transcription technique to include not only mRNA, but 
any RNAs (ncRNA, tRNAs, snoRNAs, snRNAs, ncRNAs, rRNAs) in the cell lysate.  
 
MATERIALS AND METHODS 
 Growth conditions— Wild type S. cerevisiae and Hmt1 -/- cells were generously 
received from Dr. Michael Yu at the University of Buffalo, and kept at -80°C. A swab of 
each cell line was grown on YEPD media plates for 48 hours at 30°C. Three colonies of 
each cell type were picked and grown separately in 50 mL YEPD liquid culture for 
shaking for approximately 8 hours at 30°C. At OD .6, 4 µg/mL thiolution was added and 
incubated for an additional 45 min, following which the cells were pelleted at 3,000xg, 
fast frozen in liquid nitrogen, and stored at -80°C. 
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 Hot phenol RNA extraction— Frozen cells were thawed on ice, resuspended in 
residual liquid, and transferred to a micro centrifuge tube. The cells were pelleted at 
14,000 RPM at 4°C and the supe discarded. The pellet was resuspended in 500 µL TES 
(10 mM Tris [pH 7.5], 10 mM EDTA, 5% SDS, RNase-free) and 500 µL acid phenol was 
added and the mixture incubated at 65°C for 60 min with vortexing every 10 min. The 
mixture was then iced 5 min, centrifuged at 14,000 RPM for 5 min at 4°C, and the 
supernatant removed to a new tube. An additional 500 µL phenol was added, the 
solution vortexed, incubated 5 min on ice, and then pelleted at 3000 RPM for 5 min at 
4°C. The supernatant was collected and 500 µL chloroform was added, the solution 
vortexed, and pelleted at 3000 RPM for 5 min at 4°C. The supernatant was again 
transferred, 50 µL 3M sodium acetate (pH 5.3) was added, mixed well, then 1 mL of ice-
cold 100% ethanol (RNase-free) was added and the solution placed at -20°C overnight 
to precipitate the RNA. 
 RNA purification and quantification— The precipitated RNA was pelleted at 
14,000 RPM for 10 min at 4°C, washed with 1 mL 70% ethanol (DNase-free), and air-
dried for 30 min. The dry RNA was resuspended in 500 µL DEPC H2O and the 
absorbance at 260 nm was measured using UV spectroscopy. The Turbo DNA-freeTM kit 
was used to remove DNA from 30 µg of total RNA. After DNA removal the RNA 
concentration was re-determined, and 0.3 µg was visualized on a 2% formaldehyde 
agarose gel to ensure RNA quality. 
 cDNA synthesis— 1st strand synthesis was completed using 20 µg DNA-free 
RNA for each replicate. A RNA:random primer ratio of 1:0.086 and a RNA:oligo (dT) 
ratio of 1:0.0017 were used. The initial reaction containing RNA, random primers, and 
oligo (dT) was incubated at 70°C for 10 min (denaturation) followed by 10 min at 25°C 
(annealing) and held at 4°C. The synthesis reaction consisted of the annealed mixture, 
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20 µL 5X 1st strand buffer, 10 µL 0.1M DTT, 5 µL dNTP + dUTP mix, 10 µL Superscript II 
reverse transcriptase, and DEPC H2O to 105 µL. This reaction was placed in a thermal 
cycler and the following program run: 25°C for 10 min, 37°C for 30 min, 42°C for 30 min, 
and 70°C for 10 min to inactivate the enzyme. The template RNA was then digested by 
adding 3 µL of RNase H and 3 µL of RNase cocktail and incubating at 37°C for 20 min. 
The DNA was purified using the QIAquick PCR purification kit (Qiagen, Cat# 28104) and 
eluted from the purification column in two 15 µL volumes. The cDNA was quantified 
using UV spectroscopy measuring the absorbance at 260 nm, achieving a desired 
concentration of greater than 0.1763 µg/uL cDNA. 
 Fragmentation and labeling— This step was completed using the Affymetrix 
GeneChip WT Terminal labeling kit (Cat# 900670) according to the following protocol. In 
a 0.2 mL PCR tube, 5.5 µg cDNA and water were added to a total volume of 31.2 µL. A 
reaction mixture was prepared per reaction consisting of 10 µL DEPC H2O, 4.8 µL cDNA 
fragmentation buffer, 1.0 µL UDG (10 U/µL), and 1.0 µL APE (1000 U/µL). The cDNA 
was added to this reaction mixture and pulse spun, and run through the following 
program in a thermal cycler: 37°C for 60 min, 93°C for 2 min, and 4°C for greater than 2 
min. Labeling was done immediately following the fragmentation by adding 45 µL of the 
fragmented cDNA, 12 µL 5X TdT buffer, 2 µL of TdT, and 1 µL of DNA labeling reagent 
into a PCR tube. The labeling reaction was performed in a thermal cycler using the 
following program: 37°C for 60 min, 70°C for 10 min, and 4°C for greater than 2 min. 
 Hybridization and statistical analysis— The labeled cDNA fragments were sent to 
our local Affymetrix core facility, the Center for Integrated Biotechnology (CIB), Utah 
State University, for hybridization to the GeneChip Yeast Genome 2.0 Array (Affymetrix 
Cat# 900554) and subsequent data collection. The generated data was sent for 
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statistical analysis to Dr. John Stevens in the Department of Mathematics and Statistics, 
Utah State University. 
 
RESULTS AND DISCUSSION 
 This study was directed at identifying any RNAs, including mRNAs, whose 
degradation is affected by methyl transferase activity. Both wild type (Hmt1) and Hmt1-
null (Hmt1-/-) cells were readily grown and treated with the transcriptional inhibitor 
thiolutin to stop production of new RNA. The RNA was given 45 minutes to degrade 
before the cells were harvested. The cDNA, created from the extracted RNA, was then 
fragmented and labeled for hybridization to a yeast whole-genome microarray. 
 Microarray analysis— Samples from two wild type and three Hmt1 -/- extractions 
were compared using the yeast tiling array (S. cerevisiae Tiling 1.0R Array). The third 
wild type sample was excluded due to quality concerns. The expression data gathered 
was read into R using the Starr package. Each of the 2,697,594 probes were “mapped” 
to the nearest gene, based on the starting position of the probe on the chromosome, 
using the AffyTiling package in R. Each of the genes’ positions (beginning and end) and 
chromosome were taken from the yeast\genome.org website 
(http://www.yeastgenome.org/download-data/curation, accessed 5/21/12).  There were 
8,548 ‘genes’ (or genomic regions) represented among the probes after this mapping.
 Due to the small sample size, Dr. Stevens chose a probe-level nested factorial 
model to test for differential expression between Hmt1 -/- and WT conditions, following 
RMA background correction and quantile normalization. This produced a p-value for 
each of the 8,548 genomic regions summarized as a histogram (Figure 4-1). The 
histogram plots frequency versus p-value, and a peak near zero is indicative of 
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differential expression. Unfortunately, our crippled data yielded no peak near zero, 
limiting the significance of our data.  
 Some useful information may still be garnered from this experiment by analysis 
of p-values of individual genes which are annotated to Gene Ontology or KEGG pathway 
terms can be combined (using meta-analysis tools) to give p-values for each of those 
terms. Applying this method can use subtle, non-significant, individual gene-level results 
to make statements of significance regarding the Gene Ontology or KEGG pathway 
terms. The appropriate annotation information was retrieved 
(http://www.yeastgenome.org/download-data/curation, accessed 5/21/12) and 
histograms created using this information indicate that there is strong evidence of some 
differential activity of these terms (MF = molecular function, BP = biological process, 
CC= cellular component, and KEGG) between the Hmt1 and WT conditions (Figure 4-2). 
Figure 4-1: Histogram of the probe-level nested factorial model. P-values for 
8,548 genomic regions, which compares the relative levels of RNAs in wild type 
(Hmt1) vs. Hmt1-null (Hmt1-/-) cells. 
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In correlation to our broad pathways, yeast cDNA microarray analysis of RNA 
immunoprecipitated with Myc-tagged Hmt1 from yeast cells found that Hmt1 was bound 
to genes involved in a variety of functions, including general protein synthesis, metabolic 
and catabolic pathways, creation and maintenance of cell wall, and glycolysis1. 
Unfortunately, the loss of the third wild type sample which limited the significance of 
individual RNAs put any direct gene comparisons on hold until an additional analysis of 
extracted wild type RNA can be completed.  
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CHAPTER 5 
SUMMARY AND FUTURE WORK 
REVIEW AND FUTRURE WORK 
Proteins are a type of machinery cells employ for proper function and survival. 
Creating new proteins is energetically expensive, and cells have evolved methods to 
expand existing protein function to avoid some of these costs through the use of post-
translational modifications (PTMs). Protein arginine methylation, catalyzed by protein 
arginine methyltransferases (PRMTs), is involved in a variety of biological processes, in 
cellular pathways, and human diseases (reviewed in the introduction). To further our 
understanding of how PRMTs function we have investigated the effects of 
oxidation/reduction on the recombinant PRMT1 enzyme (Chapter 2), laid a foundation 
for future work determining the specific chemical interactions between PRMTs and 
substrates (Chapter 3), and set the stage for discovery of additional roles of arginine 
methylation in RNA processing and surveillance (Chapter 4). A short summary of each 
of these projects, as well as a future direction for them, is provided below. 
 
Redox Chemistry and PRMT1 
 Our lab first discovered an increase in enzymatic activity upon the addition of the 
reductant DTT after attempts to determine the binding rate constant of AdoMet for 
PRMT1 were unsuccessful unless performed in the presence of DTT. Since then, 
assays performed in the absence and presence of DTT showed activity increases 
ranging from 1.5- to 75-fold (some data not shown) using a variety of PRMT1 constructs. 
In the absence of a reductant, PRMT1 formed a very large unordered oligomeric mass 
greater than 660 kDa. In the presence of DTT, the very large oligomeric state 
transitioned to an oligomeric state less than 660 kDa. In order to understand how the 
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PRMT1 enzyme was being reduced, I first mutated two likely cysteine residues to 
serines, purified the constructs, and assessed their activity. These mutants exhibited 
wild type characteristics, which indicated that these residues were not responsible. To 
quickly identify if any cysteine was responsible, a complete cysteine to serine PRMT1 
mutant was created. Methylation assays showed that the cysteine-less mutant no longer 
exhibited either effect of DTT.   
 Having identified that a cysteine residue is responsible for the observed redox 
chemistry, we wondered what was being changed mechanistically to slow the rate of 
catalysis (kcat). A previously established procedure, which measured intrinsic 
fluorescence quenching, was used to determine the Kd of AdoMet binding in the absence 
and presence of DTT. The Kd of AdoMet for PRMT1 was mildly enhanced (1.7-fold) upon 
the addition of DTT. However, this measurement was taken under equilibrium conditions 
and multiple rate changes could be masked in the overall Kd. We again took advantage 
of a previously established procedure, which used stopped-flow kinetics, and measured 
the association constant of AdoMet for PRMT1. We discovered that AdoMet exhibits an 
average association rate (k1) 21-fold higher in the presence of DTT. Interestingly, the 
rate of AdoMet binding in the absence of DTT (approx. 5.5s-1), while much slower than in 
the presence of DTT, is still more than 200-fold greater than the reported rate of the 
methyl transfer step (0.022s-1)1 in the presence of DTT. While this change in AdoMet 
binding does not completely explain the effects of DTT on our steady state kinetic data 
(kcat), there are many parameters in the mechanism of PRMT1 that may be affected by 
PRMT’s reduction, and therefore contribute to the steady state rate loss that have yet to 
be examined. Determination of the transient kinetics of PRMT1 in the absence and 
presence of DTT may shed additional light on which mechanistic steps are affected by 
PRMT1 reduction. 
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 The data presented in Chapter 2 have shown that the enzymatic activity of 
PRMT1 increases and the range of oligomeric states decreases upon reduction of the 
enzyme. These data seemingly conflict with a previous study by Feng et al.1 who 
showed that as the enzyme concentration is gradually increased, enzymatic activity and 
oligomeric state increase to a plateau around 0.5 µM enzyme concentration. Merging our 
study with theirs, we propose a hypothesis in which there is an extremely dynamic 
equilibrium of oligomeric states which is regulated by both enzyme concentration and 
oxidized/reduced enzyme states (Figure 5-1). On one side of the equilibrium, in a 
reduced environment at low concentrations, Feng et al.1 has shown predominantly 
monomers and dimers. On the opposite side of equilibrium, in an oxidized environment 
at high concentrations, we have shown predominantly very large molecular weight 
oligomers (>660kDa). We propose that increasing the concentration above 0.5 µM and 
maintaining a reduced enzyme generates an equilibrium oligomeric state, a mixture of 
Figure 5-1: Pictorial representation of our PRMT1 equilibrium hypothesis. 
Equilibrium of PRMT1 oligomerization shown by Feng et al. (left), data presented in 
this thesis (right), and the hypothesized oligomeric equilibrium which exhibits 
maximal enzymatic activity (middle). 
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oligomers ranging in size from 42 to 600 kDa, which exhibit maximal enzymatic activity. 
Coincidently, it is widely known that the cytosol is a reducing environment, and 
unpublished data from our lab estimates the cellular concentration of PRMT1 to be 
between 0.5 and 1.0 µM. 
 It is therefore essential that we discover any oxidation and reduction of PRMT1 
occurring in vivo, which may consequently regulate arginine methylation. To identify if 
PRMT1 is oxidized in vivo, we propose to measure the differences in the amount of free 
thiols on PRMT1 in wild type and oxidatively stressed cells. Briefly, mammalian cells 
treated to mimic oxidative stress can be lysed in the presence of a thiol capping agent, 
such as iodoacetamide, which irreversibly reacts with all free protein thiols. This capping 
agent does not react with oxidized thiols such as cysteines which are reversibly oxidized 
to disulfides and sulfenic acids, or irreversibly oxidized to sulfinic and sulfonic acids. Any 
reversible oxidation states can then be reduced which generates free thiols. These free 
thiols can then be re-labeled using a different thiol-reactive reagent capable of producing 
a measurable signal, such as fluorescence. Labeled PRMT1 can then be isolated by 
immunoprecipitation (commercial antibodies available) and the amount of thiol oxidation 
quantified.  
While this does not directly prove that oxidation of PRMT1 in vivo is associated 
with a decrease in enzymatic activity, we may extend this study using an activity probe 
developed by Thompson et al.2. This fluorescent activity probe is a peptide-based 
inhibitor compound, in which the substrate arginine is replaced with a 
choloroacetamidine warhead, capable of irreversibly bonding with PRMT1. Previous 
studies have shown that this activity probe can be used in vivo to assess PRMT1 
activity2. Alternatively, the enzymatic activity of immunoprecipitated PRMT1 may be 
tested using an established autoradiograph assay. Data showing lower enzymatic 
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activity of PRMT1 generated in oxidatively stressed cells would indicate a novel 
mechanism for regulating PRMT1 activity by oxidation and reduction of the enzyme. 
 
Identifying Chemical Interactions between Hmt1 and Peptide Substrates 
 While much is known about the mechanism of PRMTs and the variety of 
substrates they interact with, very little is understood about how PRMTs selectively bind 
their substrates. Understanding the chemical details of how PRMTs target other proteins 
for methylation sets the stage for therapeutic inhibitor development capable of 
isoenzyme, substrate, and methylation state specificity. One of the many PRMT crystals 
used to model PRMT structures (ratPRMT1) was co-crystallized with the R3 peptide 
substrate and AdoMet3. Unfortunately, the R3 peptide backbone was modeled in three 
orientations and the collected x-ray diffraction data was not sufficient to model the side 
chain interactions of the peptide with PRMT1. After structural alignment of the rat 
PRMT1 structure with the yeast Hmt1 structure, we modeled the three peptide 
backbones onto Hmt1. Using this in silico model, we hypothesized that we could disrupt 
peptide binding in two of the three putative grooves using site-directed mutagenesis.  
 Site-directed mutagenesis was used to create single-residue mutants with the 
potential to block peptide binding. Initial methyltransferase assays with the R3 peptide 
and three carefully designed asymmetric peptides did not clearly identify any mutants 
capable of forming a homogenous complex; however there is a large discrepancy in the 
activity of wild type Hmt1 in multiple preparations which hinders our ability to compare 
mutant activities to that of wild type. In addition, the lack of consistent wild type activity 
questions the validity of each of the mutant’s true activities. To continue this project we 
much first eliminate the inconsistencies in wild type Hmt1 activity. A recent study showed 
that phosphorylation of serine 9 (or a S9E mutation) was required for oligomerization 
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and enzymatic activity in vivo4. Creating a S9E mutant will allow us to assay a 
phosphorylated Hmt1 mimic. If this Hmt1 mutant, which better mimics in vivo realities, 
yields consistent enzymatic activity, all mutants developed to sterically hinder peptide 
binding will need to have this mutation introduced and be characterized again. After 
achieving reliable enzymatic activity data which identifies a mutant(s) or multi-mutant(s) 
capable of methylating only one peptide, the mutant:peptide combination(s) should be 
put into crystal trials as a potentially homogenous Hmt1:peptide complex. This 
homogenous protein crystal should be capable of generating x-ray diffraction data which 
resolves specific chemical interactions between the side chains of the peptide and the 
Hmt1 core. Identification of these interactions would lay a solid foundation for the in silico 
development of PRMT inhibitors capable isoenzyme, substrate, and methylation state 
selectivity. 
 
Whole Genome Microarray Analysis of Total RNA Levels in S. cerevisiae 
 Proteins play an important role in RNA processing and surveillance in order to 
form mature messenger RNAs (mRNAs)5–7. Hmt1 has been shown to be important in 
these processes; however our understanding of what role arginine methylation plays is 
limited.  A previous study evaluated the levels of mRNAs in both wild type and Hmt1-null 
yeast cell extracts and observed greater than 2-fold changes in 64 genes5. Hmt1 has 
been shown to be inhibited by the proteins Air1 and Air2, members of the TRAMP 
complex8. The TRAMP complex is responsible for many events in RNA processing and 
is speculated to enable the nuclear exosome to efficiently degrade structured RNA9. 
Since Hmt1 is regulated by a component of this complex, we sought to expand the 
previous mRNA study by analyzing what mRNAs were affected by the loss of Hmt1 
during RNA degradation. In addition, since the TRAMP complex interacts with tRNAs, 
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snoRNAs, snRNAs, ncRNAs, rRNAs, some mRNAs, and cryptic unstable transcripts, we 
sought to analyze all RNAs, not just mRNAs, present in our yeast cell extracts.  
 To do this analysis, we stopped production of new RNA during cell growth (using 
the RNA polymerase inhibitor thiolutin) and allowed sufficient time for RNAs to undergo 
degradation. The RNA was then extracted and assayed using a S. cerevisiae whole 
genome microarray from Affymetrix. Unfortunately, one of our triplicate wild type 
samples did not produce usable data and our statistical analysis was not sufficient to see 
differences in specific genes. A broader perspective on RNA changes was obtained by 
combining individual genes into pathway groups, identifying four pathways terms with 
statistical changes in the wild type vs. Hmt1-null cells. These pathways include 
molecular function, biological processes, and cellular components. In order for individual 
gene analysis to become statistically significant additional data sets will need to be 
gathered, which is cost-prohibitive. Once an additional hybridization is performed the 
data can be re-analyzed and individual genes which change significantly when 
comparing the wild type vs Hmt1-null cells can be identified, which will provide a 
framework for further study of these individual genes. 
 
SUMMARY 
 This thesis focused on understanding the effects of oxidation and reduction on 
the enzymatic activity, oligomeric state, and mechanism of PRMT1. This project 
currently has the most potential impact in the PRMT field because of its strong 
implications, currently unmentioned in the literature, that PRMT activity may be regulated 
by oxidative stress in vivo. In addition, this thesis describes the foundation for two 
additional avenues of investigation into little understood areas in the PRMT field. The 
first of these areas seeks to understand how PRMTs target substrates by identifying 
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enzyme:substrate interactions at the atomic level. The second area investigates the 
changes in total RNA levels influenced by the presence of Hmt1 in order to understand 
what role arginine methylation plays in RNA processing and surveillance. Together, 
these studies provide a foundation for future research which addresses the exciting 
potential for oxidative regulation, the intricacies of substrate selectivity, and the role(s) of 
arginine methylation in transcriptional regulation. 
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